Tipiracil

Tipiracil
Clinical data
License data
Pharmacokinetic data
Bioavailability≥27%
Protein binding<8%
Metabolism10
Elimination half-life2.1–2.4 hrs
ExcretionFaeces (50%), urine (27%)
Identifiers
  • 5-Chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H11ClN4O2
Molar mass242.66 g·mol−1
3D model (JSmol)
Solubility in water5 mg/mL (20 °C)
  • C1CC(=N)N(C1)Cc2c(c(=O)[nH]c(=O)[nH]2)Cl
  • InChI=1S/C9H11ClN4O2/c10-7-5(12-9(16)13-8(7)15)4-14-3-1-2-6(14)11/h11H,1-4H2,(H2,12,13,15,16)
  • Key:QQHMKNYGKVVGCZ-UHFFFAOYSA-N

Tipiracil is a drug used in the treatment of cancer. It is approved for use in form of the combination drug trifluridine/tipiracil for the treatment of unresectable advanced or recurrent colorectal cancer.[1]

Tipiracil helps maintain the blood concentration of trifluridine by inhibiting the enzyme thymidine phosphorylase which metabolizes trifluridine.[1][2]

  1. ^ a b "Taiho's Lonsurf(R) (trifluridine and tipiracil hydrochloride) Tablets Approved In Japan for Treatment of Advanced Metastatic Colorectal Cancer" (Press release). March 24, 2014.
  2. ^ Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, et al. (December 2014). "Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models". Oncology Reports. 32 (6): 2319–2326. doi:10.3892/or.2014.3487. PMC 4240496. PMID 25230742.